NEW ORLEANS, March 10, 2014 /PRNewswire/ -- AAOS -- I-Flow, LLC, a Kimberly-Clark Health Care Company and manufacturer of the ON-Q Pain Relief System (ON-Q), today announced top-line findings of a Frost & Sullivan whitepaper documenting clinician perspective that ON-Q delivers superior pain control over the full length of the post-operative period, and at a lower cost compared to Exparel. The full paper is scheduled for release in April 2014.
The whitepaper analyzes the literature and clinical experience behind the ON-Q Pain Relief System and Pacira's Exparel (bupivacaine liposome injectable suspension), and illuminates the most important criteria for clinicians to consider when evaluating post-operative pain management alternatives.
According to the anesthesiologists involved in the research, the actual duration of pain relief for Exparel was significantly shorter than marketed – 25 versus 72 hours. While Exparel provided better pain relief up to 12 hours, ON-Q provided superior pain relief from that point forward up to 96 hours, making it the ideal choice for longer-term pain management. Additionally, one-third of patients are receiving more than one dose of Exparel and adjunctive drugs are used in the majority of cases, adding additional costs.
"Clinicians are telling us that pain is personal, and one-size does not fit all," said Charlie Whelan, Whitepaper Lead Analyst, Frost & Sullivan. "ON-Q's ability to adapt to the changing pain relief needs that patients have over the first five days following surgery, and not just the first 12 or 24 hours, makes it the preferred choice for patients, surgeons and anesthesiologists alike."
Frost & Sullivan identified three criteria that establish ON-Q as the preferred choice of those surveyed over Exparel for post-operative pain management:
- Greater economic value across the entire post-operative period
- Proven clinical effectiveness specific to individual patient needs
- Safety and predictability rooted in evidence
"While Exparel has been touted as a more cost-effective alternative to post-operative pain pumps, the actual economics in a clinical setting suggest otherwise," noted Alan Dine, Senior Director Clinical Research, I-Flow. "With an increasing focus on minimizing excess cost, improving patient satisfaction and avoiding readmissions, it's essential for hospitals to analyze the economic impact of their post-operative pain management approach."
To schedule an interview or learn more about this whitepaper, visit I-Flow booth #6449 during the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting or email I-Flow@schwartzmsl.com.
Frost & Sullivan performed a literature search, administered a survey to a random sample of 31 anesthesiologists and 32 pharmacy directors at U.S. hospitals who had experience with both ON-Q and Exparel and conducted in-depth interviews with a subset of participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 50 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 45 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.
I-Flow, LLC, a Kimberly-Clark Health Care Company, is a global market leader in acute pain and ambulatory medication delivery, driving innovative clinical applications for surgical procedures and regional anesthesia that improve outcomes and advance patient care. Led by its surgical pain management line, the ON-Q Pain Relief System (ON-Q) provides reliable and simple non-narcotic, regional anesthesia therapies that are redefining post-surgical recovery by reducing many of the side effects customarily associated with narcotics. Clinical studies have shown that patients who receive ON-Q products generally get back to normal faster after surgery, resulting in shorter hospital stays, reduced costs and higher patient satisfaction. I-Flow also offers a comprehensive suite of kits and trays for performing peripheral nerve blocks, providing an unmet need and total product solution for I-Flow's clinician customers. Also as part of I-Flow's total solution, the Company offers in-depth training, education, consulting and clinical support along with medical device expertise. For more information, visit www.iflo.com.
SOURCE I-Flow, LLC